| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.CELL.2009.11.038 |
| P698 | PubMed publication ID | 20005793 |
| P2093 | author name string | Sascha Karberg | |
| P433 | issue | 6 | |
| P304 | page(s) | 1029-1031 | |
| P577 | publication date | 2009-12-01 | |
| P1433 | published in | Cell | Q655814 |
| P1476 | title | Switching on epigenetic therapy | |
| P478 | volume | 139 |
| Q51073771 | 'Default' generated neonatal regulatory T cells are hypomethylated at conserved non-coding sequence 2 and promote long-term cardiac allograft survival. |
| Q33640900 | Accessing protein methyltransferase and demethylase enzymology using microfluidic capillary electrophoresis |
| Q34129576 | Active DNA demethylation: many roads lead to Rome. |
| Q27661108 | Adding a Lysine Mimic in the Design of Potent Inhibitors of Histone Lysine Methyltransferases |
| Q34831528 | Biology of the Mi-2/NuRD Complex in SLAC (Stemness, Longevity/Ageing, and Cancer). |
| Q24338109 | Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes |
| Q28083849 | Computer-aided Molecular Design of Compounds Targeting Histone Modifying Enzymes |
| Q35048728 | DNMT1 stability is regulated by proteins coordinating deubiquitination and acetylation-driven ubiquitination |
| Q34037874 | Effects of the histone deacetylase inhibitor valproic acid on human pericytes in vitro |
| Q28076395 | Epigenetic Drugs for Multiple Sclerosis |
| Q37823067 | Epigenetic mechanisms in inflammation |
| Q37646739 | Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma |
| Q35016981 | HDAC inhibition in lupus models |
| Q30244869 | Insights in human epigenomic dynamics through comparative primate analysis |
| Q34157833 | Making memories that last a lifetime: heritable functions of self-renewing memory CD8 T cells |
| Q30570945 | Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives |
| Q47437818 | PRMT5 as a druggable target for glioblastoma therapy. |
| Q41818544 | PRMT5-PTEN molecular pathway regulates senescence and self-renewal of primary glioblastoma neurosphere cells |
| Q38175783 | Regulation of protein stability of DNA methyltransferase 1 by post-translational modifications |
| Q59645294 | Role of Environmental Epigenetics in Perinatal and Neonatal Development |
| Q34876825 | Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia |
| Q33915473 | Targeting oncogenic protein-protein interactions by diversity oriented synthesis and combinatorial chemistry approaches. |
| Q30375023 | The epigenetic paradigm in periodontitis pathogenesis. |
| Q37808311 | The epigenomic interface between genome and environment in common complex diseases |
| Q54329346 | Tumor suppressor gene BLU is frequently downregulated by promoter hypermethylation in myelodysplastic syndrome. |
| Q39221079 | Ubiquitination/deubiquitination and acetylation/deacetylation: making DNMT1 stability more coordinated |
Search more.